Since BRCA2 mutations are well known to increase the sensitivity toward PARP inhibition and, as we previously showed, to TRAIL-receptor-targeting agents [12,13,25], we next aimed at assessing the effect of BRCA2 gene status on the interaction of these agents and whether this synergy is specific to pancreatic cancer. The gene discussed is BRCA2; the disease is familial pancreatic carcinoma.